Hu Xichun, Huang Wei, Fan Minhao
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
J Hematol Oncol. 2017 Apr 28;10(1):98. doi: 10.1186/s13045-017-0466-3.
HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemotherapy is a promising field, especially for triple-negative breast cancer.
人表皮生长因子受体2（HER2）和细胞周期蛋白依赖性激酶4/6（CDK4/6）无疑是乳腺癌最重要的两个生物学靶点。抗HER2治疗可提高客观缓解率、无进展生存期/无病生存期以及总生存期。三种CDK4/6抑制剂均持续改善客观缓解率和无进展生存期；然而，总生存期数据仍有待观察。化疗和内分泌治疗策略的优化仍是未满足的需求。基于检查点抑制剂的免疫疗法联合化疗是一个有前景的领域，尤其是对于三阴性乳腺癌。
